Skip to main content
Equibles

GMAB · Genmab A/S

Track GMAB — free

Use GMAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GMAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.47 +0.24 (+0.74%) At close · Sep 11
Rebalance outlook locked
Market Cap
$19.97B
Shares
614.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.47 Open$32.45 Day$32.27–32.70 52W close$23.85–35.34 Avg vol 30d2.5M Short int6.8M · 1.1% float · 2.4d Short vol46% Last earningsAug 6, 2026 DataJan 2020–Sep 2026

Up next

Next earnings call
Nov 6, 2026 Est · unconfirmed · in 8 wks

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.13B
Trailing 12 months
Net income (TTM)
$788.00M
Trailing 12 months
Revenue growth YoY
+24.9%
Year over year
Operating margin
26.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
4.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+13.5%
Trailing year
Short interest
1.1%
Latest settlement · 2.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +5%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 75%
mid-range
Momentum
relative strength
Very Strong
1-month return +4%
trailing
6-month return +29%
trailing
YTD return +5%
this year
Relative strength +12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $31 › 200d $29 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.11% of float · ▼ -10.1% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
293 holders — near 3-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 33%
annualized · 1-yr
Max drawdown −33%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
75% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $31 › 200d $29 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.11% of float · ▼ -10.1% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
293 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $32 · 75% Range high $35
vs 200-day avg +10% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GMAB
Genmab A/S
this stock
$19.97B +5.4% — — 1.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
293
% held
17.4%
Net QoQ
+24.9M sh
Top holder
Paradigm Biocapital Advis…
Held Float
View
Held by Funds
Fund positions
50
View
Short & Settlement
Short Interest Falling
Shares short
6.8M
Days to cover
2.4d
Change
-767.9K sh
View
Short Volume
Short vol %
46%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
378
Value
$11.8K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
34.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$50.0K–$100.0K
Traded
Jul 10, 2023
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 9, 2026
This year
46
View
Proposed Sales
Value
$67.2K
Shares
1.3K
Filed
Jun 17, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
GMAB -5.6% +3.6% +29.4% -2.1% +5.4%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.5% +5.4% +11.5% -1.7% -6.7%
Key facts CIK 1434265 CUSIP 372303206 13F (30d) 80 filings 79 filers Visit website Investor relations